Clinical Trial Update: Sintilimab in Combination With Chidamide in Refractory and Relapsed ENKTCL [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating sintilimab combined with chidamide for refractory and relapsed extranodal NK/T-cell lymphoma (ENKTL) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma
• Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Huiqiang Huang | Conditions: Safety and Efficacy | Phase 1, Phase 2 | Status: COMPLETED